The_DT
financial_JJ
statements_NOMZ
of_PIN
the_DT
Group_NN
are_VPRT [PASS]
prepared_VBN
in_PIN
accordance_NN
with_PIN
UK_NN
GAAP_NN
Generally_RB
Accepted_JJ
Accounting_GER
Principles_NN
which_WDT [WHSUB]
differs_VPRT
in_PIN
certain_JJ
respects_NN
from_PIN
US_FPP1
GAAP_NN
._.
The_DT
tables_NN
below_PLACE
summarise_NN
the_DT
material_NN
adjustments_NOMZ
to_PIN
the_DT
loss_NN
for_PIN
the_DT
year_NN
and_PHC
shareholders_NN
funds_NN
which_WDT [WHSUB]
would_PRMD
be_VB [PASS]
required_VBN [SUAV]
if_COND
US_FPP1
GAAP_NN
had_VBD [PEAS]
been_VBN [PASS]
applied_VBN
instead_CONJ
of_NULL
UK_NN
GAAP_NN
._.
Year_NN
to_PIN
Year_NN
to_PIN
31_CD
December_NN
2002_CD
31_CD
December_NN
2001_CD
Notes_NN
000_CD
000_CD
Profit_NN
loss_NN
under_IN
UK_NN
GAAP_NN
1,109_CD
9,452_CD
US_FPP1
GAAP_NN
adjustments_NOMZ
:_:
Purchase_NN
accounting_GER
and_PHC
goodwill_NN
Amortisation_NOMZ
of_PIN
goodwill_NN
and_CC
other_JJ
intangibles_NN
I_FPP1
3,399_CD
5,708_CD
Depreciation_NOMZ
of_PIN
tangible_JJ
fixed_JJ
assets_NN
II_NN
518_CD
488_CD
Write-off_PIN
of_PIN
acquired_VBN
in-process_JJ
research_NN
and_PHC
development_NOMZ
costs_NN
III_NN
4,646_CD
18,893_CD
Results_NN
in_PIN
equity_NOMZ
investments_NOMZ
RTP_NN
III_NN
559_CD
Deferred_JJ
taxes_NN
III_NN
401_CD
Share-based_JJ
compensation_NOMZ
IX_CD
181_CD
215_CD
Revenue_NN
recognition_NOMZ
VII_NN
26,987_CD
1,934_CD
Sale_NN
of_PIN
royalty_NN
interests_NN
Revenue_NN
recognition_NOMZ
VIII_NN
14,219_CD
6,342_CD
Interest_NN
expense_NN
VIII_NN
5,850_CD
1,222_CD
Royalty_NN
payments_NOMZ
VIII_NN
664_CD
Financial_NN
instruments_NOMZ
XI_NN
531_CD
31_CD
Net_JJ
loss_NN
under_IN
US_FPP1
GAAP_NN
45,261_CD
43,868_CD
Net_JJ
loss_NN
per_PIN
Ordinary_NN
Share_NN
under_IN
US_FPP1
GAAP_NN
pence_NN
7.8_CD
p_NN
8.3_CD
p_NN
Shareholders_NN
funds_NN
Year_NN
to_PIN
Year_NN
to_PIN
31_CD
December_NN
2002_CD
31_CD
December_NN
2001_CD
Notes_NN
000_CD
000_CD
Shareholders_NN
funds_NN
under_IN
UK_NN
GAAP_NN
124,270_CD
95,145_CD
US_FPP1
GAAP_NN
adjustments_NOMZ
:_:
Purchase_NN
accounting_GER
and_PHC
goodwill_NN
Goodwill_NN
I_FPP1
,_,
III_NN
83,719_CD
73,259_CD
Other_JJ
intangible_JJ
fixed_JJ
assets_NN
I_FPP1
4,344_CD
5,174_CD
Tangible_JJ
fixed_JJ
assets_NN
II_NN
7,930_CD
7,192_CD
Investments_NOMZ
III_NN
1,893_CD
796_CD
Deferred_JJ
taxes_NN
III_NN
1,439_CD
2,738_CD
Contingent_JJ
consideration_NOMZ
charged_VBN [WZPAST]
to_PIN
goodwill_NN
reserve_NN
V_NN
22,620_CD
27,457_CD
Shares_NN
issued_VBN
relating_VBG
to_PIN
contingent_JJ
consideration_NOMZ
VI_NN
11,310_CD
Shares_NN
and_PHC
warrants_NN
to_TO
be_VB [PASS]
issued_VBN
,_,
deferred_VBN
shares_NN
and_PHC
shares_NN
issued_VBN [WZPAST]
to_PIN
Dr_NN
Gonella_NN
IV_NN
11,310_CD
34,070_CD
Share-based_JJ
compensation_NOMZ
IX_CD
305_CD
193_CD
Employee_NN
Benefit_NN
Trust_NN
X_NN
1,859_CD
552_CD
Deferred_JJ
revenue_NN
VII_NN
23,179_CD
771_CD
Funding_GER
liabilities_NOMZ
VIII_NN
37,698_CD
15,256_CD
Financial_NN
instruments_NOMZ
XI_NN
500_CD
31_CD
Shareholders_NN
funds_NN
under_IN
US_FPP1
GAAP_NN
138,530_CD
142,570_CD
reconciliation_NOMZ
to_PIN
US_FPP1
82_CD
accounting_GER
principles_NN
SkyePharma_NN
annual_JJ
report_NN
2002_CD
SkyePharma_NN
annual_JJ
report_NN
2002_CD
Summary_NN
of_PIN
Material_NN
Differences_NN
between_PIN
UK_NN
and_PHC
US_FPP1
GAAP_NN
Under_IN
US_FPP1
GAAP_NN
,_,
contingent_JJ
consideration_NOMZ
is_VPRT [PASS]
recognized_VBN [PRIV]
only_DWNT
when_RB
determinable_JJ
beyond_IN
reasonable_JJ
doubt_NN
,_,
therefore_CONJ
deferred_VBN
shares_NN
I_FPP1
Goodwill_NN
and_CC
other_JJ
intangible_JJ
fixed_JJ
assets_NN
Prior_RB
to_PIN
the_DT
introduction_NOMZ
of_PIN
and_CC
shares_NN
and_PHC
warrants_NN
to_TO
be_VB [PASS]
issued_VBN
have_VPRT [PEAS]
been_VBN [PASS]
reversed_VBN
out_PIN
of_PIN
FRS10_NN
,_,
as_IN
permissible_JJ
under_IN
UK_NN
GAAP_NN
,_,
no_SYNE
intangible_JJ
assets_NN
had_VBD [PEAS]
been_VBN
shareholders_NN
funds_NN
under_IN
US_FPP1
GAAP_NN
._.
recognized_VBN [PRIV]
as_CONJ
a_NULL
result_NULL
of_PIN
purchase_NN
accounting_GER
as_IN
the_DT
intangible_JJ
assets_NN
In_CONJ
addition_NULL
,_,
under_IN
UK_NN
GAAP_NN
in_PIN
connection_NOMZ
with_PIN
the_DT
acquisition_NOMZ
of_PIN
RTP_NN
,_,
were_VBD [PASS]
considered_VBN [PRIV]
to_TO
be_VB [BEMA]
an_DT
integral_JJ
part_NN
of_PIN
the_DT
business_NOMZ
acquired_VBD
and_CC
5.8_CD
million_CD
of_PIN
the_DT
total_JJ
consideration_NOMZ
was_VBD [BEMA]
payable_PRED
in_PIN
shares_NN
which_WDT [WHSUB]
were_VBD [PASS]
were_VBD
,_,
therefore_CONJ
,_,
included_VBD
within_PIN
goodwill_NN
and_CC
eliminated_VBN
against_PIN
issued_VBN
subsequent_JJ
to_PIN
31_CD
December_NN
2001_CD
._.
As_IN
of_PIN
31_CD
December_NN
2001_CD
,_,
these_DEMO
shareholders_NN
funds_NN
._.
Where_RB
the_DT
aggregate_NN
of_PIN
the_DT
fair_JJ
values_NN
of_PIN
the_DT
net_JJ
shares_NN
had_VBD [PEAS]
been_VBN [PASS]
included_VBN
within_PIN
shareholders_NN
funds_NN
and_PHC
warrants_NN
to_TO
be_VB [PASS]
assets_NN
acquired_VBN
exceeded_VBD
the_DT
cost_NN
of_PIN
the_DT
acquired_VBN
net_JJ
assets_NN
resulting_VBG [WZPRES]
issued_VBN
._.
Under_IN
US_FPP1
GAAP_NN
,_,
such_JJ
amounts_NN
would_PRMD
be_VB [PASS]
recorded_VBN
as_IN
a_DT
liability_NOMZ
in_PIN
negative_JJ
goodwill_NN
,_,
such_JJ
excess_NN
was_VBD [PASS]
credited_VBN
directly_RB
to_PIN
reserves_NN
._.
The_DT
until_IN
the_DT
shares_NN
are_VPRT [PASS]
issued_VBN
._.
Group_NN
adopted_VBD
transitional_JJ
provisions_NN
under_IN
FRS10_NN
and_CC
accordingly_RB
did_VBD [PROD]
V_NN
Contingent_NN
consideration_NOMZ
charged_VBD
to_PIN
goodwill_NN
The_DT
Group_NN
effected_VBD
the_DT
not_XX0
reinstate_VB
goodwill_NN
previously_TIME
eliminated_VBN
against_PIN
reserves_NN
as_IN
an_DT
acquisition_NOMZ
of_PIN
Krypton_NN
and_PHC
Jago_NN
through_PIN
the_DT
exchange_NN
of_PIN
warrants_NN
and_CC
intangible_JJ
asset_NN
._.
The_DT
issuance_NN
of_PIN
certain_JJ
of_PIN
these_DEMO
warrants_NN
and_PHC
shares_NN
is_VPRT
US_FPP1
GAAP_NN
requires_VPRT [SUAV]
an_DT
allocation_NOMZ
of_PIN
the_DT
purchase_NN
consideration_NOMZ
to_PIN
contingent_JJ
upon_PIN
the_DT
occurrence_NN
of_PIN
certain_JJ
future_JJ
events_NN
._.
Under_IN
UK_NN
identifiable_JJ
intangible_JJ
assets_NN
,_,
including_VBG [PRESP]
any_QUAN
resulting_VBG
from_PIN
research_NN
GAAP_NN
,_,
the_DT
Group_NN
estimated_VBD [PRIV]
the_DT
fair_JJ
value_NN
of_PIN
the_DT
contingent_JJ
consideration_NOMZ
and_PHC
development_NOMZ
._.
Goodwill_NN
and_CC
identifiable_JJ
intangible_JJ
fixed_JJ
assets_NN
are_VPRT
to_TO
determine_VB [SUAV] [PRIV]
the_DT
acquisition_NOMZ
cost_NN
._.
The_DT
resulting_VBG
goodwill_NN
was_VBD [PASS]
eliminated_VBN
reflected_VBN [PRIV]
as_IN
assets_NN
._.
Prior_RB
to_PIN
2002_CD
,_,
goodwill_NN
was_VBD [PASS]
amortised_VBN
over_IN
its_PIT
useful_JJ
against_PIN
shareholders_NN
funds_NN
._.
life_NN
,_,
with_PIN
the_DT
exception_NOMZ
of_PIN
goodwill_NN
arising_VBG [WZPRES]
on_PIN
acquisitions_NOMZ
made_VBN
after_IN
Under_IN
US_FPP1
GAAP_NN
the_DT
acquisition_NOMZ
cost_NN
has_VPRT [PEAS]
been_VBN [PASS]
adjusted_VBN
to_TO
remove_VB
30_CD
June_NN
2001_CD
._.
Effective_JJ
1_CD
January_NN
2002_CD
goodwill_NN
is_VPRT [SPAU] [PASS]
no_RB
longer_RB
amortised_VBN
the_DT
contingent_JJ
consideration_NOMZ
,_,
which_WDT [SERE]
is_VPRT [SPAU] [PASS]
only_DWNT
recognized_VBN [PRIV]
when_RB [WHCL]
it_PIT
under_IN
US_FPP1
GAAP_NN
,_,
but_CC
instead_CONJ
subject_JJ
to_PIN
annual_JJ
impairment_NOMZ
tests_NN
._.
This_DEMP
is_VPRT [BEMA]
determinable_PRED
beyond_IN
reasonable_JJ
doubt_NN
,_,
therefore_CONJ
contingent_JJ
results_NN
in_PIN
a_DT
reversal_NN
of_PIN
goodwill_NN
amortisation_NOMZ
charged_VBN
under_IN
UK_NN
GAAP_NN
._.
consideration_NOMZ
charged_VBD
to_PIN
goodwill_NN
reserves_NN
has_VPRT [PEAS]
been_VBN [BEMA]
reversed_JJ
Intangible_JJ
fixed_JJ
assets_NN
recognized_VBN [PRIV]
under_IN
US_FPP1
GAAP_NN
purchase_NN
accounting_GER
out_PIN
of_PIN
shareholders_NN
funds_NN
under_IN
US_FPP1
GAAP_NN
._.
requirements_NOMZ
are_VPRT [PASS]
amortised_VBN
over_IN
their_TPP3
estimated_VBN [PRIV] [THATD]
revenue_NN
earning_VBG [WZPRES]
life_NN
._.
Negative_JJ
goodwill_NN
,_,
if_COND
any_QUAN
,_,
is_VPRT [BYPA]
eliminated_VBN
by_PIN
reducing_VBG
the_DT
value_NN
of_PIN
all_QUAN
VI_NN
Shares_NN
issued_VBD
related_VBN
to_PIN
contingent_JJ
consideration_NOMZ
In_PIN
April_NN
2002_CD
,_,
all_QUAN
non-current_JJ
assets_NN
acquired_VBN
._.
contingencies_NN
related_VBN [WZPAST]
to_PIN
the_DT
Deferred_NN
A_NN
Shares_NN
were_VBD [PASS]
removed_VBN
based_VBN
on_PIN
the_DT
first_JJ
commercial_JJ
launch_NN
of_PIN
Paxil_NN
CR_NN
._.
In_PIN
connection_NOMZ
with_PIN
the_DT
removal_NN
II_NN
Tangible_JJ
fixed_VBN
assets_NN
Prior_RB
to_PIN
the_DT
introduction_NOMZ
of_PIN
FRS10_CD
under_IN
UK_NN
GAAP_NN
of_PIN
these_DEMO
contingencies_NN
,_,
in_PIN
2002_CD
the_DT
Group_NN
issued_VBD
12_CD
million_CD
Ordinary_NN
for_PIN
business_NOMZ
acquisitions_NOMZ
,_,
where_RB
the_DT
aggregate_NN
of_PIN
the_DT
fair_JJ
values_NN
of_PIN
Shares_NN
to_PIN
Dr._NN
Gonella_NN
,_,
the_DT
vendor_NN
of_PIN
Jago_NN
._.
Under_IN
US_FPP1
GAAP_NN
,_,
these_DEMO
shares_NN
the_DT
net_JJ
assets_NN
acquired_VBN
exceeded_VBD
the_DT
cost_NN
of_PIN
the_DT
acquired_VBN
net_JJ
assets_NN
were_VBD [PASS]
recorded_VBN
within_PIN
shareholders_NN
funds_NN
at_PIN
the_DT
market_NN
value_NN
at_PIN
the_DT
date_NN
resulting_VBG [WZPRES]
in_PIN
negative_JJ
goodwill_NN
,_,
such_JJ
excess_NN
was_VBD [PASS]
credited_VBN
directly_RB
to_PIN
the_DT
contingencies_NN
were_VBD [PASS]
removed_VBN
._.
Under_IN
US_FPP1
GAAP_NN
such_JJ
excess_NN
is_VPRT [BYPA]
eliminated_VBN
by_PIN
proportionately_RB
reducing_VBG
the_DT
value_NN
of_PIN
the_DT
non-current_JJ
assets_NN
acquired_VBN
._.
Under_IN
UK_NN
GAAP_NN
the_DT
shares_NN
were_VBD [PASS]
recorded_VBN
at_PIN
the_DT
market_NN
price_NN
at_PIN
the_DT
date_NN
of_PIN
issuance_NN
of_PIN
deferred_JJ
shares_NN
20_CD
July_NN
2000_CD
._.
The_DT
adjustment_NOMZ
III_NN
Acquired_VBD
in-process_JJ
research_NN
and_PHC
development_NOMZ
costs_NN
The_DT
Group_NN
reverses_VPRT
the_DT
value_NN
of_PIN
equity_NOMZ
share_NN
capital_NN
and_PHC
premium_NN
in_PIN
the_DT
amount_NN
of_PIN
acquired_VBN
the_DT
drug_NN
delivery_NN
business_NOMZ
of_PIN
Bioglan_NN
AB_NN
for_PIN
3.6_CD
million_CD
and_CC
11.3_CD
million_CD
._.
A_DT
corresponding_JJ
adjustment_NOMZ
in_PIN
the_DT
amount_NN
of_PIN
9.4_CD
million_CD
the_DT
assumption_NOMZ
of_PIN
0.4_CD
million_CD
of_PIN
net_JJ
liabilities_NOMZ
in_PIN
May_POMD
2002_CD
,_,
as_IN
described_VBN
has_VPRT [PEAS]
been_VBN [PASS]
recorded_VBN
within_PIN
Goodwill_NN
and_CC
other_JJ
intangible_JJ
fixed_JJ
assets_NN
that_DEMO
in_PIN
note_NN
27_CD
:_:
Acquisitions_NOMZ
._.
In_PIN
determining_VBG [SUAV] [PRIV]
the_DT
allocation_NOMZ
of_PIN
the_DT
purchase_NN
represents_VPRT
the_DT
fair_JJ
value_NN
of_PIN
shares_NN
issued_VBN
under_IN
US_FPP1
GAAP_NN
._.
price_NN
to_PIN
assets_NN
and_PHC
liabilities_NOMZ
acquired_VBN
,_,
the_DT
Group_NN
valued_VBN
acquired_VBN
inprocess_JJ
research_NN
and_PHC
development_NOMZ
that_TSUB
had_VBD
no_SYNE
other_JJ
alternative_JJ
use_NN
at_PIN
VII_NN
Revenue_NN
recognition_NOMZ
Under_IN
US_FPP1
GAAP_NN
,_,
more_EMPH
prescriptive_JJ
criteria_NN
than_PIN
5.1_CD
million_CD
which_WDT
created_VBD
negative_JJ
goodwill_NN
of_PIN
1.1_CD
million_CD
which_WDT
was_VBD
UK_NN
GAAP_NN
have_VPRT [PEAS]
been_VBN [PASS]
applied_VBN
to_TO
assess_VB
whether_IN
the_DT
culmination_NOMZ
of_PIN
the_DT
allocated_VBN
among_PIN
non-current_JJ
assets_NN
acquired_VBN
._.
Accordingly_RB
,_,
the_DT
fair_JJ
value_NN
earnings_GER
process_NN
has_VPRT [PEAS]
been_VBN [PASS]
completed_VBN
and_ANDC
whether_IN
the_DT
Group_NN
has_VPRT
of_PIN
non-current_JJ
asset_NN
acquired_VBN [WZPAST]
in_PIN
the_DT
amount_NN
of_PIN
0.7_CD
million_CD
was_VBD [PASS]
reduced_VBN
continuing_VBG
obligations_NOMZ
throughout_PIN
the_DT
contract_NN
term_NN
._.
As_CONJ
a_NULL
result_NULL
,_,
under_IN
to_TO
nil_VB
and_CC
4.6_CD
million_CD
of_PIN
in-process_JJ
research_NN
and_PHC
development_NOMZ
was_VBD
US_FPP1
GAAP_NN
certain_JJ
non-refundable_JJ
up-front_JJ
payments_NOMZ
have_VPRT [PEAS]
been_VBN [PASS]
deferred_VBN
expensed_VBN
in_PIN
the_DT
period_NN
of_PIN
acquisition_NOMZ
._.
over_IN
the_DT
development_NOMZ
period_NN
of_PIN
the_DT
contract_NN
term_NN
on_PIN
certain_JJ
agreements_NOMZ
._.
In_PIN
2001_CD
,_,
the_DT
Group_NN
purchased_VBD
the_DT
majority_NOMZ
interest_NN
of_PIN
RTP_NN
through_PIN
a_DT
twoDeferred_JJ
revenue_NN
reflects_VPRT [PRIV]
the_DT
amount_NN
of_PIN
revenue_NN
not_XX0
currently_RB
eligible_JJ
for_PIN
step_NN
acquisition_NOMZ
effected_VBD
in_PIN
July_NN
and_PHC
December_NN
2001_CD
._.
The_DT
acquisition_NOMZ
was_VBD
recognition_NOMZ
under_IN
US_FPP1
GAAP_NN
as_RB
well_RB
as_IN
the_DT
reversal_NN
of_PIN
7.8_CD
million_CD
4.8_CD
recorded_VBN
using_VBG
the_DT
purchase_NN
method_NN
of_PIN
accounting_GER
under_IN
both_DT
UK_NN
and_CC
million_CD
as_IN
of_PIN
31_CD
December_NN
2001_CD
deferred_JJ
revenue_NN
under_IN
UK_NN
GAAP_NN
related_JJ
US_FPP1
GAAP_NN
._.
to_PIN
the_DT
sale_NN
of_PIN
royalty_NN
interests_NN
,_,
which_WDT [SERE]
is_VPRT [PASS]
treated_VBN
as_IN
debt_NN
under_IN
US_FPP1
GAAP_NN
._.
The_DT
adjustments_NOMZ
between_PIN
UK_NN
and_PHC
US_FPP1
GAAP_NN
in_PIN
respect_NN
of_PIN
the_DT
RTP_NN
VIII_NN
Sale_NN
of_PIN
royalty_NN
interests_NN
Under_IN
UK_NN
GAAP_NN
payments_NOMZ
received_VBD
from_PIN
a_DT
acquisition_NOMZ
relate_VB
mainly_RB
to_PIN
differences_NN
in_PIN
the_DT
valuation_NOMZ
of_PIN
purchase_NN
third_JJ
party_NN
to_TO
fund_VB
the_DT
internal_JJ
research_NN
and_PHC
development_NOMZ
of_PIN
a_DT
product_NN
in_PIN
price_NN
consideration_NOMZ
,_,
the_DT
methods_NN
of_PIN
purchase_NN
price_NN
allocation_NOMZ
and_CC
the_DT
return_NN
for_PIN
the_DT
sale_NN
of_PIN
a_DT
proportion_NOMZ
of_PIN
potential_JJ
future_JJ
royalty_NN
streams_NN
from_PIN
amortisation_NOMZ
of_PIN
goodwill_NN
._.
In_PIN
2001_CD
,_,
this_DEMP
resulted_VBD
in_PIN
a_DT
5.3_CD
million_CD
increase_NN
a_DT
selection_NOMZ
of_PIN
products_NN
are_VPRT [PASS]
reflected_VBN [PRIV]
within_PIN
other_JJ
operating_GER
income_NN
when_RB
in_PIN
purchase_NN
consideration_NOMZ
and_PHC
differences_NN
in_PIN
the_DT
amounts_NN
assigned_VBN [WZPAST]
to_PIN
the_DT
risk_NN
of_PIN
reimbursement_NOMZ
has_VPRT [SPAU] [PEAS]
effectively_RB
been_VBN [PASS]
transferred_VBN
to_PIN
the_DT
third_JJ
certain_JJ
tangible_JJ
and_PHC
intangible_JJ
fixed_VBN
assets_NN
,_,
investments_NOMZ
and_CC
related_VBN
party_NN
._.
Royalties_NN
repaid_VBN [WZPAST]
to_PIN
third_JJ
parties_NN
are_VPRT [PASS]
treated_VBN
as_IN
cost_NN
of_PIN
goods_NN
sold_VBN
._.
Under_IN
US_FPP1
GAAP_NN
amounts_VPRT
allocated_VBN
to_TO
acquired_VBN
in-process_JJ
US_FPP1
GAAP_NN
requires_VPRT [SUAV]
such_JJ
funding_GER
payments_NOMZ
to_TO
be_VB [PASS]
recorded_VBN
as_IN
debt_NN
where_RB
research_NN
and_PHC
development_NOMZ
that_TSUB
do_VPRT
not_XX0
have_VB
an_DT
alternative_JJ
use_NN
have_VPRT [PEAS]
been_VBN
there_EX
is_VPRT
continuing_VBG
involvement_NOMZ
in_PIN
the_DT
generation_NOMZ
of_PIN
the_DT
cash_NN
flows_VPRT
due_JJ
to_TO
expensed_VBN
through_PIN
earnings_GER
in_PIN
the_DT
period_NN
of_PIN
acquisition_NOMZ
:_:
under_IN
UK_NN
GAAP_NN
,_,
the_DT
third_JJ
party_NN
._.
The_DT
US_FPP1
GAAP_NN
adjustment_NOMZ
for_PIN
the_DT
statement_NOMZ
of_PIN
operations_NOMZ
certain_JJ
of_PIN
these_DEMO
amounts_NN
are_VPRT [PASS]
not_XX0
separately_RB
identified_VBN
but_CC
considered_VBN [PRIV]
includes_VPRT
the_DT
reversal_NN
of_PIN
funding_GER
revenue_NN
recorded_VBN [WZPAST]
from_PIN
the_DT
third_JJ
party_NN
as_IN
part_NN
of_PIN
goodwill_NN
._.
In_CONJ
addition_NULL
,_,
under_IN
UK_NN
GAAP_NN
goodwill_NN
is_VPRT
being_VBG [PASS]
amortised_VBN
well_RB
as_IN
recording_VBG
the_DT
interest_NN
charge_NN
for_PIN
the_DT
period_NN
on_PIN
the_DT
outstanding_JJ
over_IN
20_CD
years_NN
on_PIN
a_DT
straight-line_JJ
basis_NN
while_OSUB
under_IN
US_FPP1
GAAP_NN
,_,
goodwill_NN
funding_GER
liability_NOMZ
balance_NN
._.
Repayments_NOMZ
made_VBD
to_PIN
third_JJ
parties_NN
in_PIN
the_DT
form_NN
of_PIN
resulting_VBG
from_PIN
this_DEMO
acquisition_NOMZ
was_VBD [PASS]
not_XX0
amortised_VBN
._.
royalty_NN
payments_NOMZ
that_TSUB
are_VPRT [PASS]
expensed_VBN
under_IN
UK_NN
GAAP_NN
are_VPRT [PASS]
reversed_VBN
under_IN
IV_NN
Deferred_NN
shares_NN
and_PHC
shares_NN
and_PHC
warrants_NN
to_TO
be_VB [PASS]
issued_VBN
Under_IN
UK_NN
GAAP_NN
,_,
US_FPP1
GAAP_NN
since_OSUB
they_TPP3
are_VPRT [PASS]
treated_VBN
as_IN
repayment_NOMZ
of_PIN
debt_NN
._.
contingent_JJ
consideration_NOMZ
payable_JJ
in_PIN
connection_NOMZ
with_PIN
the_DT
acquisition_NOMZ
IX_CD
Share-based_JJ
compensation_NOMZ
Under_IN
US_FPP1
GAAP_NN
,_,
the_DT
Group_NN
applies_VPRT
of_PIN
Jago_NN
is_VPRT [PASS]
included_VBN
within_PIN
shareholders_NN
funds_NN
as_IN
deferred_JJ
shares_NN
._.
Accounting_GER
Principles_NN
Board_NN
Opinion_NN
APB_NN
No._NN
._.
25_CD
,_,
Accounting_GER
for_PIN
Stock_NN
As_IN
of_PIN
31_CD
December_NN
2001_CD
,_,
the_DT
Group_NN
had_VBD [SPAU] [PEAS]
also_RB
recorded_VBN
contingent_JJ
Issued_VBN
to_PIN
Employees_NN
,_,
and_ANDC
related_JJ
interpretations_NOMZ
in_PIN
accounting_GER
for_PIN
its_PIT
consideration_NOMZ
payable_JJ
within_PIN
shareholders_NN
funds_NN
in_PIN
the_DT
amount_NN
of_PIN
plans_NN
._.
Accordingly_RB
,_,
a_DT
compensation_NOMZ
expense_NN
has_VPRT [PEAS]
been_VBN [PASS]
recognized_VBN [PRIV]
for_PIN
4.8_CD
million_CD
in_PIN
connection_NOMZ
with_PIN
the_DT
acquisition_NOMZ
of_PIN
Krypton_NN
._.
The_DT
amount_NN
performance-based_JJ
compensation_NOMZ
plans_NN
where_RB
it_PIT
is_VPRT [BEMA]
probable_PRED
that_THAC
the_DT
at_PIN
31_CD
December_NN
2002_CD
related_VBN
to_PIN
Krypton_NN
was_VBD
nil_NN
._.
83_CD
Summary_NN
of_PIN
Material_NN
Differences_NN
between_PIN
UK_NN
and_PHC
US_FPP1
GAAP_NN
continued_VBD
XIII_NN
Recent_JJ
U._NN
S._NN
GAAP_NN
Pronouncements_NOMZ
In_PIN
August_NN
2001_CD
,_,
the_DT
FASB_NN
issued_VBD
SFAS_NN
No._NN
._.
143_CD
,_,
Accounting_GER
for_PIN
Obligations_NOMZ
Associated_NN
with_PIN
the_DT
performance_NN
criteria_NN
will_PRMD
be_VB [PASS]
met_VBN
and_CC
the_DT
options_NOMZ
exercised_VBN [WZPAST]
prior_RB
to_PIN
the_DT
Retirement_NOMZ
of_PIN
Long-Lived_NN
Assets_NN
._.
This_DEMO
standard_NN
will_PRMD
be_VB [BEMA]
effective_PRED
for_PIN
the_DT
expiration_NOMZ
of_PIN
the_DT
options_NOMZ
issued_VBN
under_IN
these_DEMO
plans_NN
._.
No_SYNE
compensation_NOMZ
Groups_NN
fiscal_JJ
year_NN
beginning_VBG [WZPRES]
1_CD
January_NN
2003_CD
._.
The_DT
standard_JJ
requires_VPRT [SUAV]
that_THVC
expense_NN
has_VPRT [PEAS]
been_VBN [PASS]
recognized_VBN [PRIV]
for_PIN
those_DEMO
plans_NN
that_TSUB
are_VPRT [PASS]
considered_VBN [PRIV]
fixed_VBN
such_JJ
obligations_NOMZ
be_VB [PASS]
capitalized_VBN
as_IN
part_NN
of_PIN
the_DT
assets_NN
cost_NN
at_PIN
the_DT
time_NN
of_PIN
option_NOMZ
plans_NN
under_IN
APB_NN
25_CD
and_ANDC
where_RB
the_DT
options_NOMZ
granted_VBN [SUAV]
under_IN
the_DT
plans_NN
initial_JJ
recognition_NOMZ
,_,
with_PIN
the_DT
related_VBN
liability_NOMZ
discounted_VBN [WZPAST]
to_PIN
its_PIT
fair_JJ
value_NN
at_PIN
are_VPRT [PASS]
granted_VBN [SUAV]
at_PIN
a_DT
price_NN
that_TSUB
equals_VPRT
the_DT
market_NN
price_NN
at_PIN
the_DT
date_NN
of_PIN
grant_NN
._.
The_DT
income_NN
statement_NOMZ
impact_NN
of_PIN
adopting_VBG
this_DEMO
X_NN
Employee_NN
Benefit_NN
Trust_NN
Under_IN
UK_NN
GAAP_NN
the_DT
Ordinary_NN
Shares_NN
of_PIN
the_DT
standard_NN
will_PRMD
be_VB [PASS]
presented_VBN
as_IN
a_DT
cumulative_JJ
effect_NN
of_PIN
a_DT
change_NN
in_PIN
Company_NN
held_VBN [PRIV] [WZPAST]
by_PIN
the_DT
SkyePharma_NN
PLC_NN
General_NN
Employee_NN
Benefit_NN
Trust_NN
accounting_GER
principle_NN
._.
The_DT
Group_NN
does_VPRT
not_XX0
believe_VB [PRIV]
the_DT
adoption_NOMZ
of_PIN
this_DEMP
are_VPRT [PASS]
recorded_VBN
at_PIN
cost_NN
and_CC
accounted_VBD
for_PIN
as_IN
investments_NOMZ
._.
The_DT
value_NN
of_PIN
standard_NN
will_PRMD
have_VB
a_DT
material_NN
impact_NN
on_PIN
its_PIT
financial_JJ
position_NOMZ
or_CC
results_NN
shares_NN
and_PHC
options_NOMZ
granted_VBN [SUAV] [WZPAST]
are_VPRT [PASS]
deducted_VBN
from_PIN
the_DT
cost_NN
value_NN
of_PIN
shares_NN
of_PIN
operations_NOMZ
._.
held_VBN [PRIV] [PASTP]
in_PIN
the_DT
Employee_NN
Benefit_NN
Trust_NN
and_CC
charged_VBN
to_PIN
current_JJ
period_NN
In_PIN
April_NN
2002_CD
,_,
the_DT
FASB_NN
issued_VBD
SFAS_NN
No._NN
._.
This_DEMO
standard_NN
will_PRMD
require_VB [SUAV]
expense_NN
or_CC
over_IN
the_DT
vesting_JJ
period_NN
if_COND
options_NOMZ
vest_NN
over_IN
a_DT
period_NN
of_PIN
time_NN
._.
gains_NN
and_PHC
losses_NN
from_PIN
extinguishment_NOMZ
of_PIN
debt_NN
to_TO
be_VB [PASS]
classified_VBN
as_IN
Under_IN
US_FPP1
GAAP_NN
the_DT
Ordinary_NN
Shares_NN
of_PIN
the_DT
Company_NN
purchased_VBD
extraordinary_JJ
items_NN
only_DWNT
if_COND
they_TPP3
meet_VPRT
certain_JJ
criteria_NN
._.
Any_QUAN
gain_NN
or_CC
loss_NN
by_PIN
the_DT
Employee_NN
Benefit_NN
Trust_NN
are_VPRT [PASS]
accounted_VBN
for_PIN
at_PIN
cost_NN
as_IN
treasury_NN
on_PIN
extinguishment_NOMZ
will_PRMD
be_VB [PASS]
recorded_VBN
in_PIN
the_DT
most_EMPH
appropriate_JJ
line_NN
item_NN
to_PIN
shares_NN
which_WDT [WHSUB]
reduce_VPRT
shareholders_NN
funds_NN
._.
Gains_NN
or_CC
losses_NN
arising_VBG [WZPRES]
which_WDT
it_PIT
relates_VPRT
within_PIN
net_JJ
income_NN
before_IN
extraordinary_JJ
items_NN
._.
SFAS_NN
145_CD
on_PIN
subsequent_JJ
issuance_NN
of_PIN
the_DT
shares_NN
to_PIN
employees_NN
are_VPRT [PASS]
recorded_VBN
as_IN
is_VPRT [BEMA]
effective_PRED
for_PIN
fiscal_JJ
years_NN
beginning_VBG [WZPRES]
after_IN
15_CD
May_POMD
2002_CD
._.
However_CONJ
,_,
certain_JJ
adjustments_NOMZ
to_PIN
shareholders_NN
funds_NN
._.
The_DT
reduction_NOMZ
in_PIN
cost_NN
,_,
which_WDT [SERE]
is_VPRT
sections_NOMZ
are_VPRT [BEMA]
effective_PRED
for_PIN
transactions_NOMZ
occurring_VBG [WZPRES]
after_IN
15_CD
May_POMD
2002_CD
._.
The_DT
expensed_VBN
under_IN
UK_NN
GAAP_NN
,_,
is_VPRT [PASS]
reversed_VBN
under_IN
US_FPP1
GAAP_NN
to_TO
maintain_VB [PUBV] [THATD]
the_DT
Group_NN
does_VPRT
not_XX0
expect_VB [PRIV]
the_DT
adoption_NOMZ
of_PIN
this_DEMO
standard_NN
will_PRMD
have_VB
a_DT
material_NN
treasury_NN
shares_NN
at_PIN
cost_NN
._.
All_QUAN
employee_NN
compensation_NOMZ
expense_NN
is_VPRT [PASS]
recorded_VBN
impact_NN
on_PIN
its_PIT
financial_JJ
position_NOMZ
or_CC
results_NN
of_PIN
operations_NOMZ
._.
SFAS_NN
146_CD
Accounting_GER
Costs_NN
Associated_NN
with_PIN
Exit_NN
or_CC
Disposal_NN
Activities_NOMZ
,_,
XI_NN
Financial_NN
Instruments_NOMZ
Under_IN
UK_NN
GAAP_NN
,_,
periodic_JJ
gains_NN
and_PHC
losses_NN
on_PIN
which_WDT [PIRE]
was_VBD [PASS]
issued_VBN
at_PIN
the_DT
end_NN
of_PIN
June_NN
2002_CD
,_,
addresses_NN
issues_NN
regarding_VBG [WZPRES]
interest_NN
and_CC
foreign_JJ
currency_NN
derivatives_NN
are_VPRT [PASS]
not_XX0
recognized_VBN [PRIV]
until_IN
the_DT
the_DT
recognition_NOMZ
,_,
measurement_NOMZ
,_,
and_ANDC
reporting_GER
of_PIN
costs_NN
associated_VBN [WZPAST]
with_PIN
operational_JJ
transactions_NOMZ
to_PIN
which_WDT [PIRE]
they_TPP3
are_VPRT [PASS]
linked_VBN
occur_VPRT
._.
Under_IN
US_FPP1
GAAP_NN
,_,
exit_NN
and_PHC
disposal_NN
activities_NOMZ
,_,
including_VBG
restructuring_GER
activities_NOMZ
._.
This_DEMO
the_DT
Group_NN
records_NN
all_QUAN
derivative_JJ
instruments_NOMZ
on_PIN
the_DT
balance_NN
sheet_NN
at_PIN
fair_JJ
standard_NN
will_PRMD
be_VB [PASS]
implemented_VBN
with_PIN
effect_NN
from_PIN
1_CD
January_NN
2003_CD
._.
The_DT
value_NN
with_PIN
changes_NN
in_PIN
fair_JJ
values_NN
are_VPRT [PASS]
recorded_VBN
in_PIN
earnings_GER
._.
The_DT
Group_NN
Group_NN
does_VPRT
not_XX0
expect_VB [PRIV]
the_DT
adoption_NOMZ
of_PIN
this_DEMO
standard_NN
will_PRMD
have_VB
a_DT
material_NN
has_VPRT [SPAU] [PEAS]
also_RB
reviewed_VBN
its_PIT
contractual_JJ
arrangements_NOMZ
for_PIN
the_DT
existence_NN
of_PIN
impact_NN
on_PIN
its_PIT
financial_JJ
position_NOMZ
or_CC
results_NN
of_PIN
operations_NOMZ
._.
embedded_VBN
derivatives_NN
that_TSUB
should_NEMD
be_VB [SPAU] [PASS]
separately_RB
accounted_VBN
for_PIN
under_IN
In_PIN
November_NN
2002_CD
,_,
the_DT
FASB_NN
issued_VBD
Interpretation_NOMZ
No._NN
._.
If_COND
embedded_VBN
derivatives_NN
are_VPRT [PASS]
identified_VBN
,_,
they_TPP3
are_VPRT [PASS]
recorded_VBN
Guarantors_NN
Accounting_GER
and_PHC
Disclosure_NN
Requirements_NOMZ
for_PIN
Guarantees_NN
,_,
separately_RB
from_PIN
their_TPP3
host_NN
contracts_NN
at_PIN
fair_JJ
value_NN
,_,
with_PIN
changes_NN
in_PIN
fair_JJ
Including_VBG
Indirect_JJ
Guarantees_NN
of_PIN
Indebtedness_NOMZ
of_PIN
Others_NN
._.
FIN_NN
45_CD
expands_VPRT
value_NN
recognized_VBN [PRIV] [WZPAST]
in_PIN
current_JJ
earnings_GER
._.
on_PIN
the_DT
accounting_GER
guidance_NN
of_PIN
other_JJ
SFASs_NN
FIN_NN
45_CD
elaborates_NN
on_PIN
the_DT
XII_NN
Adoption_NOMZ
of_PIN
US_FPP1
GAAP_NN
Pronouncements_NOMZ
On_PIN
1_CD
January_NN
2002_CD
the_DT
Group_NN
existing_VBG [WZPRES]
disclosure_NN
requirements_NOMZ
for_PIN
most_EMPH
guarantees_NN
,_,
including_VBG
loan_NN
adopted_VBN
SFAS_NN
No._NN
._.
142_CD
Goodwill_NN
and_CC
Other_JJ
Intangible_NN
Assets_NN
._.
SFAS_NN
142_CD
guarantees_NN
such_JJ
as_IN
standby_JJ
letters_NN
of_PIN
credit_NN
._.
It_PIT
also_RB
clarifies_VPRT
that_DEMO
at_PIN
the_DT
requires_VPRT [SUAV]
that_THVC
goodwill_NN
will_PRMD [SPAU]
no_RB
longer_RB
be_VB [PASS]
amortised_VBN
over_IN
its_PIT
estimated_JJ
time_NN
a_DT
company_NN
issues_VPRT
a_DT
guarantee_NN
,_,
it_PIT
must_NEMD
recognize_VB [PRIV]
an_DT
initial_JJ
liability_NOMZ
useful_JJ
life_NN
._.
The_DT
Group_NN
must_NEMD [SPAU]
instead_CONJ
identify_VB
and_PHC
value_VB
its_PIT
reporting_VBG [PUBV]
units_NN
for_PIN
the_DT
fair_JJ
value_NN
,_,
or_CC
market_NN
value_NN
,_,
of_PIN
the_DT
obligations_NOMZ
it_PIT
assumes_VPRT [PRIV]
under_IN
for_PIN
the_DT
purpose_NN
of_PIN
assessing_VBG
,_,
at_PIN
least_JJ
annually_RB
,_,
potential_JJ
impairment_NOMZ
of_PIN
that_DEMO
guarantee_NN
and_CC
must_NEMD
disclose_VB [PUBV]
that_THVC
information_NOMZ
in_PIN
its_PIT
interim_JJ
and_CC
goodwill_NN
allocated_VBN [WZPAST]
to_PIN
each_QUAN
reporting_VBG [PUBV]
unit_NN
._.
Separate_JJ
intangible_JJ
assets_NN
with_PIN
annual_JJ
financial_JJ
statements_NOMZ
._.
FIN_NN
45_CD
will_PRMD
be_VB [PASS]
implemented_VBN
on_PIN
a_DT
finite_JJ
lives_NN
continue_VPRT
to_TO
be_VB [PASS]
amortised_VBN
over_IN
their_TPP3
useful_JJ
lives_NN
._.
During_PIN
the_DT
prospective_JJ
basis_NN
to_PIN
guarantees_NN
issued_VBN
or_CC
modified_VBN
after_IN
31_CD
December_NN
second_JJ
quarter_NN
of_PIN
2002_CD
,_,
the_DT
Group_NN
completed_VBD
the_DT
transitional_JJ
goodwill_NN
2002_CD
._.
The_DT
disclosure_NN
requirements_NOMZ
in_PIN
this_DEMO
Interpretation_NOMZ
are_VPRT [BEMA]
effective_JJ
impairment_NOMZ
test_NN
prescribed_VBN [WZPAST]
in_PIN
SFAS_NN
142_CD
with_PIN
respect_NN
to_TO
existing_VBG
goodwill_NN
._.
forfinancial_JJ
statements_NOMZ
of_PIN
periods_NN
ending_VBG [WZPRES]
after_IN
15_CD
December_NN
2002_CD
._.
The_DT
transitional_JJ
goodwill_NN
impairment_NOMZ
test_NN
involved_VBD
a_DT
comparison_NN
of_PIN
the_DT
The_NN
Group_NN
is_VPRT [SPAU]
currently_RB
evaluating_VBG
the_DT
impact_NN
of_PIN
this_DEMO
interpretation_NOMZ
fair_JJ
value_NN
of_PIN
the_DT
Groups_NN
reporting_VBG [PUBV] [WZPRES]
unit_NN
,_,
as_IN
defined_VBN
under_IN
SFAS_NN
142_CD
,_,
with_PIN
on_PIN
its_PIT
financial_JJ
position_NOMZ
and_PHC
results_NN
of_PIN
operations_NOMZ
._.
its_PIT
carrying_VBG
amount_NN
as_IN
of_PIN
the_DT
adoption_NOMZ
date_NN
._.
As_CONJ
a_NULL
result_NULL
of_PIN
the_DT
transitional_JJ
In_PIN
January_NN
2003_CD
,_,
the_DT
FASB_NN
issued_VBD
Interpretation_NOMZ
No._NN
._.
46_CD
,_,
Consolidation_NOMZ
impairment_NOMZ
tests_NN
performed_VBN
as_IN
of_PIN
1_CD
January_NN
2002_CD
,_,
there_EX
was_VBD
no_SYNE
indicator_NN
of_PIN
Variable_JJ
Interest_NN
Entities_NOMZ
FIN_NN
46_CD
._.
Under_IN
this_DEMO
interpretation_NOMZ
,_,
certain_JJ
of_PIN
goodwill_NN
impairment_NOMZ
._.
entities_NOMZ
known_VBN [PRIV]
as_IN
Variable_JJ
Interest_NN
Entities_NOMZ
VIE_VPRT
must_NEMD
be_VB [BEMA]
consolidated_PRED
If_COND
the_DT
Group_NN
had_VBD [PEAS]
accounted_VBN
for_PIN
goodwill_NN
under_IN
SFAS_NN
142_CD
for_PIN
the_DT
year_NN
by_PIN
the_DT
primary_JJ
beneficiary_NN
of_PIN
the_DT
entity_NOMZ
._.
The_DT
primary_JJ
beneficiary_NN
is_VPRT [PASS]
ended_VBN
31_CD
December_NN
2001_CD
,_,
the_DT
impact_NN
on_PIN
reported_VBN [PUBV]
US_FPP1
GAAP_NN
results_NN
generally_RB
defined_VBN
as_IN
having_VBG
the_DT
majority_NOMZ
of_PIN
the_DT
risks_NN
and_PHC
rewards_NN
arising_VBG [WZPRES]
would_PRMD
have_VB [PEAS]
been_VBN
as_IN
follows_VPRT
:_:
from_PIN
the_DT
VIE_NN
._.
For_PIN
VIEs_NN
in_PIN
which_WDT [PIRE]
a_DT
significant_JJ
but_CC
not_XX0
majority_NOMZ
variable_JJ
interest_NN
is_VPRT [PASS]
held_VBN [PRIV]
,_,
certain_JJ
disclosures_NN
are_VPRT [PASS]
required_VBN [SUAV]
._.
The_DT
measurement_NOMZ
000_CD
principles_NN
of_PIN
this_DEMO
interpretation_NOMZ
will_PRMD
be_VB [BEMA]
effective_PRED
for_PIN
the_DT
Groups_NN
Net_JJ
loss_NN
under_IN
US_FPP1
GAAP_NN
43,868_CD
31_CD
December_NN
2003_CD
financial_JJ
statements_NOMZ
._.
The_DT
Group_NN
is_VPRT [SPAU]
currently_RB
assessing_VBG
the_DT
impact_NN
of_PIN
this_DEMO
interpretation_NOMZ
on_PIN
its_PIT
financial_JJ
position_NOMZ
Add_VB [PUBV]
:_:
Goodwill_NN
amortisation_NOMZ
8,552_CD
and_CC
results_NN
of_PIN
operations_NOMZ
._.
Adjust_VB
net_JJ
loss_NN
under_IN
US_FPP1
GAAP_NN
35,316_CD
Adjusted_VBN
basic_JJ
and_PHC
diluted_JJ
loss_NN
per_PIN
Ordinary_NN
Share_NN
under_IN
US_FPP1
GAAP_NN
pence_NN
6.7_CD
p_NN
On_PIN
1_CD
January_NN
2002_CD
the_DT
Group_NN
adopted_VBD
SFAS_NN
No._NN
._.
144_CD
,_,
Accounting_GER
for_PIN
the_DT
Impairment_NOMZ
or_CC
Disposal_NN
of_PIN
Long-Lived_NN
Assets_NN
._.
SFAS_NN
144_CD
develops_VPRT
one_CD
accounting_GER
model_NN
for_PIN
long-lived_JJ
assets_NN
,_,
including_VBG
discontinued_VBN
operations_NOMZ
to_TO
be_VB [PASS]
disposed_VBN
of_PIN
by_PIN
sale_NN
._.
It_PIT
requires_VPRT [SUAV]
that_THVC
all_QUAN
long-lived_JJ
assets_NN
be_VB [PASS]
measured_VBN
at_PIN
the_DT
lower_JJ
of_PIN
carrying_VBG
amount_NN
or_CC
fair_JJ
value_NN
less_RB
cost_VBN
to_TO
sell_VB
whether_IN
reported_VBN [PUBV]
in_PIN
continuing_VBG
or_CC
discontinued_VBN
operations_NOMZ
._.
The_DT
adoption_NOMZ
of_PIN
SFAS_NN
144_CD
has_VPRT [PEAS]
not_XX0
had_VBD
a_DT
material_NN
impact_NN
on_PIN
the_DT
Groups_NN
financial_JJ
position_NOMZ
or_CC
results_NN
of_PIN
operations_NOMZ
._.
reconciliation_NOMZ
to_PIN
US_FPP1
84_CD
accounting_GER
principles_NN
continued_VBD
SkyePharma_NN
annual_JJ
report_NN
2002_CD
Company_NN
information_NOMZ
and_PHC
advisors_NN
Registered_NN
and_PHC
Head_NN
Office_NN
Joint_NN
Corporate_NN
Brokers_NN
105_CD
Piccadilly_NN
,_,
Merrill_NN
Lynch_NN
International_NN
London_NN
W1J_NN
7NJ_NN
Ropemaker_NN
Place_NN
Telephone_NN
:_:
020 7491 1777_CD
25_CD
Ropemaker_NN
Street_NN
Fax_NN
:_:
020 7491 3338_CD
London_NN
EC2Y_NN
9LY_NN
Registered_NN
No_NN
:_:
107582_CD
Secretary_NN
:_:
Douglas_NN
Parkhill_NN
Socit_NN
Gnrale_NN
Exchange_NN
House_NN
Auditors_NN
Primrose_NN
Street_NN
LLP_NN
London_NN
EC4A_NN
2DD_NN
Chartered_NN
Accountants_NN
1_CD
Embankment_NOMZ
Place_NN
Bankers_NN
London_NN
WC2N_NN
6RH_NN
National_NN
Westminster_NN
Bank_NN
plc_NN
Bishopsgate_NN
Business_NOMZ
Centre_NN
Solicitors_NN
PO_NN
Box_NN
34_CD
UK_NN
15_CD
Bishopsgate_NN
Stringer_NN
Saul_NN
London_NN
EC2P_NN
2AP_NN
17_CD
Hanover_NN
Square_NN
London_NN
W1S_NN
1HU_NN
Registrars_NN
Capita_NN
Registrars_NN
US_FPP1
Bourne_NN
House_NN
Sullivan_NN
&_CC
Cromwell_NN
34_CD
Beckenham_NN
Road_NN
St._NN
Olaves_NN
House_NN
Beckenham_NN
9a_CD
Ironmonger_NN
Lane_NN
Kent_NN
BR3_NN
4TU_NN
London_NN
EC2V_NN
8EY_NN
Depository_NN
Investment_NOMZ
Bankers_NN
The_NN
Bank_NN
of_PIN
New_NN
York_NN
Merrill_NN
Lynch_NN
International_NN
101_CD
Barclay_NN
Street_NN
Ropemaker_NN
Place_NN
New_NN
York_NN
25_CD
Ropemaker_NN
Street_NN
NY_NN
10286_CD
London_NN
EC2Y_NN
9LY_NN
USA_NN
Designed_NN
and_CC
produced_VBN
by_PIN
Addison_NN
www_NN
._.
